Related Experiment Videos
Clinical trials in Alzheimer disease: debate on the use of placebo controls
C H Kawas1, C M Clark, M R Farlow
1Department of Neurology and Alzheimer's Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.
Abstract:
During the past 10 years, there has been a rapidly growing number of pharmaceutical industry-sponsored drug trials for treatment of Alzheimer disease (AD) and other neurodegenerative diseases. As public awareness and concerns about AD have grown, so has interest in developing drug therapies for retarding symptom progression, delaying onset, and ultimately curing the disease. Ethical debate on the use of placebo control trials in AD research has come of age in the United States with the availability of treatments approved by the Food and Drug Administration. The experts and the public agree that more effective therapies are necessary, and new therapeutic options are being developed as rapidly as possible. The arguments on each side of the debate are provocative and important but do not provide unequivocal justification for either the abandonment or the maintenance of placebo-controlled trials in all AD research. Clinical trials differ with respect to scientific and practical goals, and these factors inherently affect the ethical priorities of each study. We present these contrasting points of view to delineate some of the issues rather than to make specific recommendations other than to urge that all clinical trials in AD should be designed with careful consideration of the ethical issues surrounding the use of placebo controls. As new and more effective treatments emerge, the ethical framework for placebo use in AD studies will require frequent re-examination. To make wise choices, patients, caregivers, physicians, and ethicists (among others) must have a voice in this continuing discussion.
Insights
The ethical debate surrounding placebo-controlled trials for Alzheimer disease (AD) treatments is ongoing. Careful consideration of ethical issues is crucial when designing AD clinical trials, especially as new therapies emerge.
Area of Science:
- Neuroscience
- Medical Ethics
- Clinical Pharmacology
Background:
- Growing public concern and pharmaceutical investment in Alzheimer disease (AD) research have intensified the need for effective treatments.
- The availability of FDA-approved therapies has brought the ethical debate on placebo-controlled trials in AD research to the forefront in the US.
Purpose of the Study:
- To explore the ethical considerations of using placebo-controlled trials in Alzheimer disease (AD) research.
- To present contrasting viewpoints on placebo use in AD clinical trials without making definitive recommendations.
Main Methods:
- Review of current ethical debates and arguments regarding placebo-controlled trials in AD research.
- Analysis of how scientific and practical goals of clinical trials influence ethical priorities.
Main Results:
- Arguments for and against placebo-controlled trials in AD research are significant but do not offer a clear consensus for universal application.
- The ethical priorities of clinical trials are inherently affected by their specific scientific and practical objectives.
Conclusions:
- Placebo-controlled trials in AD research should be designed with careful attention to ethical issues.
- The ethical framework for placebo use in AD studies requires ongoing re-evaluation as new treatments become available.
- Informed decision-making necessitates the inclusion of patients, caregivers, physicians, and ethicists in the discussion on placebo use.